NIH Reporter #5SB1DK109876-07

Minimally invasive access and aspiration of circulating lymphocytes from the thoracic duct

Award to LYMPHAXIS, INC. for developing a novel catheter device for minimally invasive lymphocyte collection from the thoracic duct, including FDA clearance preparation and commercialization efforts.

Description

Building on a half-century of innovation in transvascular access and ultrasound image guidance, LXS has developed a novel catheter device and venous access procedure to cannulate and aspirate the thoracic duct under ultrasound guidance. The company is applying for a Commercialization Readiness Pilot (CRP) award to complete development, prepare and submit for FDA clearance, ramp manufacturing, and create sales and marketing strategies in anticipation of commercial use. Completion of this CRP program will place the company in a position to launch sales with an FDA cleared device as a direct competitor to plasmapheresis and the only transvascular access device for lymphocyte collection and depletion.

View original record